Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
31.62
+0.36 (1.15%)
At close: Apr 28, 2026, 4:00 PM EDT
31.86
+0.24 (0.77%)
After-hours: Apr 28, 2026, 7:13 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 38.63, with a low estimate of 26 and a high estimate of 45. The average target predicts an increase of 22.17% from the current stock price of 31.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 5 | 5 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $38 → $42 | Strong Buy | Maintains | $38 → $42 | +32.83% | Apr 9, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $40 → $41 | Buy | Reiterates | $40 → $41 | +29.66% | Mar 4, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $38 → $42 | Strong Buy | Maintains | $38 → $42 | +32.83% | Feb 18, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $36 → $45 | Strong Buy | Maintains | $36 → $45 | +42.31% | Feb 9, 2026 |
| Barclays | Barclays | Buy Maintains $35 → $38 | Buy | Maintains | $35 → $38 | +20.18% | Jan 30, 2026 |
Financial Forecast
Revenue This Year
16.98B
from 17.26B
Decreased by -1.62%
Revenue Next Year
17.48B
from 16.98B
Increased by 2.97%
EPS This Year
2.74
from 1.21
Increased by 126.06%
EPS Next Year
3.12
from 2.74
Increased by 14.17%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.7B | 18.2B | |
| Avg | 17.0B | 17.5B | |
| Low | 16.1B | 16.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.3% | 7.1% | |
| Avg | -1.6% | 3.0% | |
| Low | -6.5% | -2.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.86 | 3.31 | |
| Avg | 2.74 | 3.12 | |
| Low | 2.56 | 2.80 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 136.0% | 20.9% | |
| Avg | 126.1% | 14.2% | |
| Low | 112.0% | 2.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.